The Correlation between the Triglyceride-Glucose Index and the Severity of Non-Alcoholic Fatty Liver Disease in Obese Patients — Oak Academic Publishing
Research ArticleOpen AccessGoogle Scholar indexed
The Correlation between the Triglyceride-Glucose Index and the Severity of Non-Alcoholic Fatty Liver Disease in Obese Patients
Medical College, School of Medicine, Wuhan University of Science and Technology, Wuhan, China
,
Department of Gastrointestinal Surgery, Puren Hospital Affiliated to Wuhan University of Science and Technology, Wuhan, China
1 Medical College, School of Medicine, Wuhan University of Science and Technology, Wuhan, China
2 Department of Gastrointestinal Surgery, Puren Hospital Affiliated to Wuhan University of Science and Technology, Wuhan, China
Objective: Non-alcoholic fatty liver disease (NAFLD) has become the most common chronic liver disease worldwide, particularly among individuals with obesity. This study aimed to investigate the association between the triglyceride-glucose (TyG) index and NAFLD severity in obese patients. Methods: This cross-sectional study included 93 obese adults from Puren Hospital Affiliated to Wuhan University of Science and Technology between January 2022 and December 2023. NAFLD severity was assessed using abdominal ultrasonography and categorized as non-severe (n = 70) or severe (n = 23). The TyG index was calculated as ln [fasting triglyceride (mg/dL) × fasting plasma glucose (mg/dL)/2]. Spearman correlation and logistic regression models, and receiver operating characteristic (ROC) analysis were used to examine associations between the TyG index and NAFLD severity. Results: Patients with severe NAFLD had significantly higher TyG indices compared to those with non-severe disease (9.40 vs. 8.83, P = 0.003). The proportion of patients with severe NAFLD was significantly higher in the high TyG group (68.8% vs. 15.6%, P Conclusion: The TyG index is significantly and independently associated with the severity of NAFLD in obese patients. As a simple and non-invasive marker, it may serve as a useful tool for early screening and risk stratification of severe NAFLD in clinical practice.
Soto-Angona, Ó., Anmella, G., Valdés-Florido, M.J., De Uribe-Viloria, N., Carvalho, A.F., Penninx, B.W.J.H., et al . (2020) Non-alcoholic Fatty Liver Disease (NAFLD) as a Neglected Metabolic Companion of Psychiatric Disorders: Common Pathways and Future Approaches. BMC Medicine , 18, Article No. 261. https://doi.org/10.1186/s12916-020-01713-8
Younossi, Z., Anstee, Q.M., Marietti, M., Hardy, T., Henry, L., Eslam, M., et al . (2018) Global Burden of NAFLD and NASH: Trends, Predictions, Risk Factors and Prevention. Nature Reviews Gastroenterology & Hepatology , 15, 11-20. https://doi.org/10.1038/nrgastro.2017.109
Younossi, Z.M., Golabi, P., Paik, J.M., Henry, A., Van Dongen, C. and Henry, L. (2023) The Global Epidemiology of Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH): A Systematic Review. Hepatology , 77, 1335-1347. https://doi.org/10.1097/hep.0000000000000004
Quek, J., Chan, K.E., Wong, Z.Y., Tan, C., Tan, B., Lim, W.H., et al . (2023) Global Prevalence of Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis in the Overweight and Obese Population: A Systematic Review and Meta-analysis. The Lancet Gastroenterology & Hepatology , 8, 20-30. https://doi.org/10.1016/s2468-1253(22)00317-x
Zhu, J., Hollis-Hansen, K., Wan, X., Fei, S., Pang, X., Meng, F., et al . (2016) Clinical Guidelines of Non-Alcoholic Fatty Liver Disease: A Systematic Review. World Journal of Gastroenterology , 22, 8226-8233. https://doi.org/10.3748/wjg.v22.i36.8226
Lonardo, A., Ballestri, S., Marchesini, G., Angulo, P. and Loria, P. (2015) Nonalcoholic Fatty Liver Disease: A Precursor of the Metabolic Syndrome. Digestive and Liver Disease , 47, 181-190. https://doi.org/10.1016/j.dld.2014.09.020
Targher, G., Tilg, H. and Byrne, C.D. (2021) Non-Alcoholic Fatty Liver Disease: A Multisystem Disease Requiring a Multidisciplinary and Holistic Approach. The Lancet Gastroenterology & Hepatology , 6, 578-588. https://doi.org/10.1016/s2468-1253(21)00020-0
Heda, R., Yazawa, M., Shi, M., Bhaskaran, M., Aloor, F.Z., Thuluvath, P.J., et al . (2021) Non-Alcoholic Fatty Liver and Chronic Kidney Disease: Retrospect, Introspect, and Prospect. World Journal of Gastroenterology , 27, 1864-1882. https://doi.org/10.3748/wjg.v27.i17.1864
Arab, J.P., Barrera, F. and Arrese, M. (2018) The Evolving Role of Liver Biopsy in Non-Alcoholic Fatty Liver Disease. Annals of Hepatology , 17, 899-902. https://doi.org/10.5604/01.3001.0012.7188
Simental-Mendía, L.E., Rodríguez-Morán, M. and Guerrero-Romero, F. (2008) The Product of Fasting Glucose and Triglycerides as Surrogate for Identifying Insulin Resistance in Apparently Healthy Subjects. Metabolic Syndrome and Related Disorders , 6, 299-304. https://doi.org/10.1089/met.2008.0034
Zhou, T. and Xie, C. (2025) Association between Triglyceride-Glucose Index and Onset of Type 2 Diabetes in Metabolic Dysfunction-Associated Steatotic Liver Disease Population. Scientific Reports , 15, Article No. 18044. https://doi.org/10.1038/s41598-025-03453-2
Son, D., Lee, H.S., Lee, Y., Lee, J. and Han, J. (2022) Comparison of Triglyceride-Glucose Index and HOMA-IR for Predicting Prevalence and Incidence of Metabolic Syndrome. Nutrition , Metabolism and Cardiovascular Diseases , 32, 596-604. https://doi.org/10.1016/j.numecd.2021.11.017
Yang, S. and Wang, Z. (2025) The Triglyceride-Glucose Index Is a Promising Predictor for the Risk of Cardiovascular Disease in the Diabetic Population Aged ≥ 60 Years in the United States: A Retrospective Cohort Study from NHANES (2007-2016). Frontiers in Endocrinology , 16, Article 1475590. https://doi.org/10.3389/fendo.2025.1475590
Watt, M.J., Miotto, P.M., De Nardo, W. and Montgomery, M.K. (2019) The Liver as an Endocrine Organ—Linking NAFLD and Insulin Resistance. Endocrine Reviews , 40, 1367-1393. https://doi.org/10.1210/er.2019-00034
Fujii, H. and Kawada, N. (2020) The Role of Insulin Resistance and Diabetes in Nonalcoholic Fatty Liver Disease. International Journal of Molecular Sciences , 21, Article 3863. https://doi.org/10.3390/ijms21113863
Nayak, S.S., Kuriyakose, D., Polisetty, L.D., Patil, A.A., Ameen, D., Bonu, R., et al . (2024) Diagnostic and Prognostic Value of Triglyceride Glucose Index: A Comprehensive Evaluation of Meta-Analysis. Cardiovascular Diabetology , 23, Article No. 310. https://doi.org/10.1186/s12933-024-02392-y
Wang, X., Liu, J., Yu, K., Huang, Z., Liu, H. and Li, X. (2025) Association between TyG-Related Parameters and NAFLD Risk in Japanese Non-Obese Population. Scientific Reports , 15, Article No. 7119. https://doi.org/10.1038/s41598-025-88478-3
Rubino, F., Cummings, D.E., Eckel, R.H., Cohen, R.V., Wilding, J.P.H., Brown, W.A., et al . (2025) Definition and Diagnostic Criteria of Clinical Obesity. The Lancet Diabetes & Endocrinology , 13, 221-262. https://doi.org/10.1016/s2213-8587(24)00316-4
Ma, Y., Zuo, L., Chen, J., Luo, Q., Yu, X., Li, Y., et al . (2006) Modified Glomerular Filtration Rate Estimating Equation for Chinese Patients with Chronic Kidney Disease. Journal of the American Society of Nephrology , 17, 2937-2944. https://doi.org/10.1681/asn.2006040368
ElSayed, N.A., McCoy, R.G., Aleppo, G., Balapattabi, K., Beverly, E.A., Briggs Early, K., et al . (2025) 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2025. Diabetes Care , 48, S27-S49. https://doi.org/10.2337/dc25-s002
McEvoy, J.W., McCarthy, C.P., Bruno, R.M., Brouwers, S., Canavan, M.D., Ceconi, C., et al . (2024) 2024 ESC Guidelines for the Management of Elevated Blood Pressure and Hypertension. European Heart Journal , 45, 3912-4018. https://doi.org/10.1093/eurheartj/ehae178
Catapano, A.L., Graham, I., De Backer, G., Wiklund, O., Chapman, M.J., Drexel, H., et al . (2016) 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. European Heart Journal , 37, 2999-3058. https://doi.org/10.1093/eurheartj/ehw272
Li, Q., Li, X., Wang, J., Liu, H., Kwong, J.S., Chen, H., et al . (2019) Diagnosis and Treatment for Hyperuricemia and Gout: A Systematic Review of Clinical Practice Guidelines and Consensus Statements. BMJ Open , 9, e026677. https://doi.org/10.1136/bmjopen-2018-026677
Ballestri, S., Lonardo, A., Romagnoli, D., Carulli, L., Losi, L., Day, C.P., et al . (2012) Ultrasonographic Fatty Liver Indicator, a Novel Score Which Rules Out NASH and Is Correlated with Metabolic Parameters in NAFLD. Liver International , 32, 1242-1252. https://doi.org/10.1111/j.1478-3231.2012.02804.x
Ramdas Nayak, V.K., Satheesh, P., Shenoy, M.T. and Kalra, S. (2022) Triglyceride Glucose (TyG) Index: A Surrogate Biomarker of Insulin Resistance. Journal of the Pakistan Medical Association , 72, 986-988. https://doi.org/10.47391/jpma.22-63
Cai, Y., Chen, J., Deng, X., Wang, B., Huang, J. and Lian, N. (2024) Triglyceride-glucose Index and Combined Indicators: Effective Indicators for Screening NAFLD in Snoring Patients. BMC Pulmonary Medicine , 24, Article No. 359. https://doi.org/10.1186/s12890-024-03166-8
Yetim, A., Şahin, M., Kandemir, İ., Bulakçı, B., Aksakal, M.T., Karapınar, E., et al . (2024) Evaluation of the Ability of Insulin Resistance and Lipid-Related Indices to Predict the Presence of NAFLD in Obese Adolescents. Lipids in Health and Disease , 23, Article No. 208. https://doi.org/10.1186/s12944-024-02144-7
Wang, X., Wang, Z., Du, W., Ma, X., Ma, J., Chen, Z., et al . (2024) Predictive Value of TyG and TyG-BMI Indices for Non-Alcoholic Fatty Liver Disease in High-Altitude Regions of China: A Cross-Sectional Study. Journal of Clinical Medicine , 13, Article 7423. https://doi.org/10.3390/jcm13237423
Mu, W., Cheng, X., Liu, Y., Lv, Q., Liu, G., Zhang, J., et al . (2019) Potential Nexus of Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus: Insulin Resistance between Hepatic and Peripheral Tissues. Frontiers in Pharmacology , 9, Article 1566. https://doi.org/10.3389/fphar.2018.01566
Smith, G.I., Shankaran, M., Yoshino, M., Schweitzer, G.G., Chondronikola, M., Beals, J.W., et al . (2020) Insulin Resistance Drives Hepatic De Novo Lipogenesis in Nonalcoholic Fatty Liver Disease. Journal of Clinical Investigation , 130, 1453-1460. https://doi.org/10.1172/jci134165
Luo, Y., Dong, X., Yu, Y., Sun, G. and Sun, X. (2015) Total Aralosides of Aralia elata (Miq) Seem (TASAES) Ameliorate Nonalcoholic Steatohepatitis by Modulating IRE1 α -Mediated JNK and NF- κ B Pathways in ApoE –/– Mice. Journal of Ethnopharmacology , 163, 241-250. https://doi.org/10.1016/j.jep.2015.01.017
Perla, F., Prelati, M., Lavorato, M., Visicchio, D. and Anania, C. (2017) The Role of Lipid and Lipoprotein Metabolism in Non‐alcoholic Fatty Liver Disease. Children , 4, Article 46. https://doi.org/10.3390/children4060046
Horn, C.L., Morales., A.L., Savard, C., Farrell, G.C. and Ioannou, G.N. (2021) Role of Cholesterol-Associated Steatohepatitis in the Development of Nash. Hepatology Communications , 6, 12-35. https://doi.org/10.1002/hep4.1801
Muniyappa, R., Iantorno, M. and Quon, M.J. (2008) An Integrated View of Insulin Resistance and Endothelial Dysfunction. Endocrinology and Metabolism Clinics of North America , 37, 685-711. https://doi.org/10.1016/j.ecl.2008.06.001
Yaribeygi, H., Farrokhi, F.R., Butler, A.E. and Sahebkar, A. (2019) Insulin Resistance: Review of the Underlying Molecular Mechanisms. Journal of Cellular Physiology , 234, 8152-8161. https://doi.org/10.1002/jcp.27603
Lee, C.J., Sears, C.L. and Maruthur, N. (2020) Gut Microbiome and Its Role in Obesity and Insulin Resistance. Annals of the New York Academy of Sciences , 1461, 37-52. https://doi.org/10.1111/nyas.14107
Fang, J., Yu, C., Li, X., Yao, J., Fang, Z., Yoon, S., et al . (2022) Gut Dysbiosis in Nonalcoholic Fatty Liver Disease: Pathogenesis, Diagnosis, and Therapeutic Implications. Frontiers in Cellular and Infection Microbiology , 12, Article 997018. https://doi.org/10.3389/fcimb.2022.997018
Gkolfakis, P., Dimitriadis, G. and Triantafyllou, K. (2015) Gut Microbiota and Non-Alcoholic Fatty Liver Disease. Hepatobiliary & Pancreatic Diseases International , 14, 572-581. https://doi.org/10.1016/s1499-3872(15)60026-1